Phuturdex › Diseases › Macular degeneration
Drugs in development · updated 30 October 2026
Macular degeneration: drugs in development
As of 30 October 2026 there are 46 active clinical trials (recruiting or ongoing, phases I–III) on 40 drugs for macular degeneration. 25 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OLN324 | III | 2 | NCT07816289 |
| Tiespectus | II–III | 2 | NCT07440225 |
| Cemdisiran | III | 1 | NCT06541704 |
| JNJ-81201887 | II–III | 1 | NCT06635148 |
| KH631 | I–II | 2 | NCT05672121 |
| KH658 | I–II | 2 | NCT06458595 |
| ABBV-6628 | I–II | 1 | NCT07160179 |
| ADVM-022 | II | 1 | NCT05536973 |
| AIV007 | II | 1 | NCT07557121 |
| BI 771716 | II | 1 | NCT06722157 |
| BRX011 | I–II | 1 | NCT07029945 |
| EG-301 | II | 1 | NCT05170048 |
| EYC-0305 | I–II | 1 | NCT07587515 |
| GAL-101 | II | 1 | NCT06659549 |
| GT005 | II | 1 | NCT05481827 |
| PST-611 | II | 1 | NCT07705568 |
| STL303 | II | 1 | NCT07606365 |
| VIS-101 | II | 1 | NCT07798375 |
| VOY-101 | I–II | 1 | NCT06087458 |
| ABF-101 | I | 1 | NCT07330674 |
| ARO-033 | I | 1 | NCT07662096 |
| ASP2020 | I | 1 | NCT07734064 |
| ASP7317 | I | 1 | NCT03178149 |
| BBC1501 | I | 1 | NCT05803785 |
| HG202 | I | 1 | NCT06623279 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AfliberceptEYLEA Injection, Ziv-Aflibercept | II–III | 12 | NCT07440225 |
| PozelimabVeopoz® | III | 2 | NCT06541704 |
| RanibizumabLucentis, Ranluspec® | II–III | 2 | NCT04704921 |
| Bevacizumabavastin, MVASI | III | 1 | NCT05112861 |
| ElamipretideForzinity® | III | 1 | NCT06373731 |
| FaricimabVabysmo® | III | 1 | NCT07461441 |
| PegcetacoplanSYFOVRE, Empaveli® | I–II | 2 | NCT07160179 |
| AtorvastatinLipitor, Atorvaliq® | II | 1 | NCT04735263 |
| Avacincaptad Pegol solutionIzervay®, Izelvay® | II | 1 | NCT06659445 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | II | 1 | NCT07174687 |
| Dimethyl FumarateTecfidera®, Dimethyl fumarate Mylan® | II | 1 | NCT04292080 |
| AcyclovirSitavig®, Avaclyr® | I | 1 | NCT03178149 |
| DisulfiramAntabuse® | I | 1 | NCT06319872 |
| NystatinMycostatin®, Nilstat® | I | 1 | NCT03178149 |
| TacrolimusEnvarsus XR, Prograf® | I | 1 | NCT03178149 |
Sorted by most advanced phase and number of active trials.
All 40 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Macular retinal edema 15 drugs
- Stargardt disease 14 drugs
- Geographic atrophy 26 drugs
- Diabetic retinopathy 17 drugs
- Wet Macular Degeneration 7 drugs
- Retinal Dystrophies 8 drugs
- Retinal degeneration 15 drugs
- Eye disease 19 drugs
- Cone-rod dystrophy 5 drugs
- Uveitis 10 drugs
- Retinal disease 18 drugs
- Blindness 6 drugs
Broader categories
- Eye disease 19 drugs
- Retinal disease 18 drugs
- Retinal degeneration 15 drugs
- Hereditary eye disease 4 drugs
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008268 “Macular Degeneration”.